Company Overview of Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. researches, develops, manufactures, markets, and sells prescription pharmaceutical products. Its products include Vivelle-Dot and Estradot, which are transdermal estrogen patches; CombiPatch and Estalis, which are combination estrogen/progestogen patches; Stavzor, a delayed release valproic acid softgel; Pexeva, a paroxetine mesylate; Lithobid, a lithium carbonate; Brisdelle, a paroxetine capsule for the treatment of vasomotor symptoms associated with menopause; and estradiol transdermal system for the prevention of postmenopausal osteoporosis. It also manufactures Daytrana, a prescription central nervous system stimulant patch system for the treatment of ADHD in ...
11960 SW 144th Street
Miami, FL 33186
Founded in 1987
Key Executives for Noven Pharmaceuticals, Inc.
Chief Executive Officer and President
Vice President of Operations
Chief Scientific Officer and Vice President
Chief Medical Officer and Executive Vice President of Product Development
Compensation as of Fiscal Year 2014.
Noven Pharmaceuticals, Inc. Key Developments
Noven Receives FDA Approval of New Indication with New Dose for Minivelle(R) (Estradiol Transdermal System)
Sep 24 14
Noven Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved a new indication with a new dose of Minivelle (estradiol transdermal system) for the prevention of postmenopausal osteoporosis. The FDA initially approved Minivelle in October 2012 to treat moderate to severe vasomotor symptoms (VMS) due to menopause, commonly known as hot flashes. With this new approval, women who are using Minivelle to treat their VMS symptoms have the benefit of also helping to prevent osteoporosis. The new 0.025 mg/day patch is 33% smaller than Minivelle 0.0375 mg/day that is already only about the size of a dime, the planet's smallest estrogen therapy patch ever. Minivelle is now approved with five dosing options -- 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day, with the newly approved, lower dose of 0.025 mg/day indicated for the prevention of postmenopausal osteoporosis only. If a patient uses Minivelle only to prevent osteoporosis from menopause, they should talk with their healthcare provider about whether a different treatment or medicine without estrogens might be better for them. The new lower dose of 0.025 mg/day is expected to be available in pharmacies in January 2015. Noven offers a savings program to help reduce the Minivelle co-pay for eligible patients. Eligible patients pay no more than $15 each month for up to 12 uses on their Minivelle prescriptions.
Noven Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014
Sep 10 14
Noven Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.
Noven Appoints Krista Roberts as Vice President of Operations
Jun 23 14
Noven Pharmaceuticals, Inc. announced the appointment of Krista Roberts as the company's new Vice President of Operations. In this role, Roberts will be responsible for all Noven manufacturing and related operations, reporting to Jeffrey Eisenberg, Noven's President and Chief Executive Officer. Roberts succeeds Richard Gilbert, who retired in April 2014. Roberts has over 15 years' experience in the pharmaceutical and medical device industries. Prior to joining Noven, she held various positions within Baxter International, serving most recently as Plant Manager of Baxter's 600+ person manufacturing facility in Cleveland, Mississippi. Her prior roles at Baxter included Director of Manufacturing, Manufacturing Manager, Manufacturing Superintendent, Department Engineer, and Manufacturing Supervisor.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|